Trial Profile
An Open-Label, Dose-Finding Study of Vedolizumab IV Plus Standard of Care for Graft-Versus-Host Disease (GvHD) Prophylaxis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Aug 2019
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary) ; Methotrexate; Tacrolimus
- Indications Graft-versus-host disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda
- 04 Dec 2018 6-month results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 11 Jul 2018 Status changed from active, no longer recruiting to completed.
- 12 Mar 2018 Planned End Date changed from 31 Dec 2018 to 22 Jun 2018.